Sources say FDA commissioner sought rejection of KalVista’s rare disease drug; FDA looks into Sarepta’s Duchenne therapy after deaths; and more

Welcome back to Endpoints Weekly! Thanks for spending your Saturday with us. We start this week’s recap with reporting from Endpoints News’ senior biopharma correspondent Andrew Dunn on the FDA’s review of KalVista Pharmaceuticals’ rare ...